Myriad Genetics takes cancer awareness to the Midwest

Share this article:
Myriad Genetics takes cancer awareness to the Midwest
Myriad Genetics takes cancer awareness to the Midwest
In an extension of a long-running hereditary breast and cancer awareness campaign, Myriad Genetics launched consumer advertising materials in five Midwest states on Monday.

The campaign targets women ages 25 to 54 with a family or personal history of breast or ovarian cancer, and physicians who care for these women on an ongoing basis, according to a spokesperson at Ogilvy, the campaign's public relations firm. Professional outreach includes educating physicians on how to identify appropriate patients. Myriad's other agency partners on the campaign include Lehman Millet and Blitz Media.

Television spots running on network channels through spring of 2010 will include branded messages for the BRACAnalysis test, a blood test that can determine a woman's level of risk for breast or ovarian cancer, although200 the overall campaign is an unbranded awareness initiative, the spokesperson said. Ads drive traffic to www.bracnow.com, and by phone to 1-866-BRACNOW. Outreach to physicians began six months ago in the form of meetings, letters and emails, the spokesperson said.

The Midwest campaign is an extension of an initiative that began in the Northeast in 2007/2008 and was rolled out in Florida and Texas last year, the spokesperson said. The current campaign is running in Illinois, Indiana, Kentucky, Missouri and Ohio.   

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...